| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-704 | |
| Phytochemical name or plant extracts | Astragalin | |
| PMID | 26922854 | |
| Literature evidence | Quercetin showed significant cytotoxic activity against HepG2 and MCF-7 cell lines with IC50 values of 4.88 and 0.87 μg/mL, respectively. | |
| IUPAC name | 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Flavonoid | |
| Source of phytochemicals or plant Extracts | Calligonum polygonoides | |
| Geographical availability | Gulf States, Iran, Iraq, Kuwait, Lebanon-Syria, Pakistan, Palestine, Saudi Arabia, Sinai, Transcaucasus, Turkey, Yemen | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Liver cancer | |
| Target gene or protein | AKT, ZEB1, VEGF, and MMP9 | |
| Gene or Protein evidence | Computational pharmacology analysis indicated that the effects of Astragalin against breast cancer were mainly related to the regulation of the cell movement, migration, and angiogenesis, and taking AKT, ZEB1, VEGF, and MMP9 as the promising targets. | |
| Target pathways | PI3K-AKT signal pathway | |
| IC50 | NA | |
| Potency | Astragalin suppresses the metastasis and angiogenesis of breast cancer, and AKT, ZEB1, VEGF, and MMP9 are the promising targets for Astragalin against breast cancer. Thus, Astragalin is a potential therapeutic agent for breast cancer. | |
| Cell line/ mice model | MCF-7, HepG2 | |
| Additional information | AST might be a promising therapeutic candidate for treating osteolytic bone diseases in the future. | |
| PubChem ID | 5282102 | |
| Additional PMIDs | 36215870 36195046 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:693386-1 | |
| Safety | NA |